Treatment of relapsed multiple myeloma: Evidence-based recommendations

Ceren Durer; Seren Durer; Sarah Lee; Rajshekhar Chakraborty; Mustafa Nadeem Malik; Abdul Rafae; Muhammad Abu Zar; Ahmad Kamal; Nathaniel Rosko; Christy Samaras; Jason Valent; Chakra Chaulagain; Faiz Anwer

doi:10.1016/j.blre.2019.100616

Treatment of relapsed multiple myeloma: Evidence-based recommendations

Ceren Durer, Seren Durer, Sarah Lee, Rajshekhar Chakraborty, Mustafa Nadeem Malik, Abdul Rafae, Muhammad Abu Zar, Ahmad Kamal, Nathaniel Rosko, Christy Samaras, Jason Valent, Chakra Chaulagain, Faiz Anwer

Medicine

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.

Original language	English (US)
Article number	100616
Journal	Blood Reviews
Volume	39
DOIs	https://doi.org/10.1016/j.blre.2019.100616
State	Published - Jan 2020

Keywords

Evidence-based
Multiple myeloma
Refractory
Relapsed
Treatment

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.blre.2019.100616

Fingerprint Dive into the research topics of 'Treatment of relapsed multiple myeloma: Evidence-based recommendations'. Together they form a unique fingerprint.

Cite this

Treatment of relapsed multiple myeloma : Evidence-based recommendations. / Durer, Ceren; Durer, Seren; Lee, Sarah; Chakraborty, Rajshekhar; Malik, Mustafa Nadeem; Rafae, Abdul; Zar, Muhammad Abu; Kamal, Ahmad; Rosko, Nathaniel; Samaras, Christy; Valent, Jason; Chaulagain, Chakra; Anwer, Faiz.

In: Blood Reviews, Vol. 39, 100616, 01.2020.

Research output: Contribution to journal › Review article › peer-review

@article{da2bfc12011746bc904de86a5ea83c75,

title = "Treatment of relapsed multiple myeloma: Evidence-based recommendations",

abstract = "The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.",

keywords = "Evidence-based, Multiple myeloma, Refractory, Relapsed, Treatment",

author = "Ceren Durer and Seren Durer and Sarah Lee and Rajshekhar Chakraborty and Malik, {Mustafa Nadeem} and Abdul Rafae and Zar, {Muhammad Abu} and Ahmad Kamal and Nathaniel Rosko and Christy Samaras and Jason Valent and Chakra Chaulagain and Faiz Anwer",

year = "2020",

month = jan,

doi = "10.1016/j.blre.2019.100616",

language = "English (US)",

volume = "39",

journal = "Blood Reviews",

issn = "0268-960X",

publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Treatment of relapsed multiple myeloma

T2 - Evidence-based recommendations

AU - Durer, Ceren

AU - Durer, Seren

AU - Lee, Sarah

AU - Chakraborty, Rajshekhar

AU - Malik, Mustafa Nadeem

AU - Rafae, Abdul

AU - Zar, Muhammad Abu

AU - Kamal, Ahmad

AU - Rosko, Nathaniel

AU - Samaras, Christy

AU - Valent, Jason

AU - Chaulagain, Chakra

AU - Anwer, Faiz

PY - 2020/1

Y1 - 2020/1

N2 - The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.

AB - The practice of choosing the next best therapy for patients with relapsed and/or refractory multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus regarding the best treatment sequence for RRMM. With the approval of novel proteasome inhibitors (ixazomib and carfilzomib), immunomodulatory agents (pomalidomide), monoclonal antibodies (daratumumab and elotuzumab), and other targeted therapies, multiple combination regimens utilizing these agents are being studied with the goal of enhancing disease control, prolonging progression-free survival, and improving overall survival. We, herein, describe a review of FDA-approved regimens for RRMM patients and offer a paradigm in selecting subsequent treatment regimens, focusing on patient specific morbidity, treatment toxicity, and disease-specific characteristics.

KW - Evidence-based

KW - Multiple myeloma

KW - Refractory

KW - Relapsed

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85071716943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071716943&partnerID=8YFLogxK

U2 - 10.1016/j.blre.2019.100616

DO - 10.1016/j.blre.2019.100616

M3 - Review article

AN - SCOPUS:85071716943

VL - 39

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

M1 - 100616

ER -